Mabwell (688062.SH), a China-based biopharmaceutical company, announced on Tuesday that it has introduced the first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011.
The study, CTR20230046, a phase one, single centre, randomised, double-blind placebo-controlled, ascending dose study, is intended to assess the safety, tolerability, pharmacokinetic, pharmacodynamics and immunogenicity of 9MW3011 in healthy adult subjects.
The product, a monoclonal antibody with an innovative target, has been independently developed at Mabwell's San Diego Innovation and R&D Center in the United States. It belongs to Category one Therapeutic Biological Products. Its target is mainly expressed on the surfaces of liver cell membranes and can upregulate the level of hepcidin expressed by hepatocytes via specific binding, inhibit the absorption and release of iron, and reduce the serum iron level, thus regulating the iron homeostasis in vivo. It has been approved for clinical study both in China and the United States.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration